Somagenetix

Zurich, Switzerland

Somagenetix is a new firm that wants to be a leader in gene therapy by developing first-in-class treatments for phagocyte-related illnesses.

$11.7M raised

Oct 2024

Series A

Top Investors

Schroders CapitalVerve VenturesZurcher Kantonal BankVI Partners

19,000+ verified contacts

Emails, phones & LinkedIn profiles

How much funding has Somagenetix raised?

Somagenetix has raised $11.7M in total funding. The most recent round was Series A. The last funding was announced in October 2024.

Who are Somagenetix's investors?

Somagenetix's investors include Schroders Capital, Verve Ventures, Zurcher Kantonal Bank, VI Partners.

Where is Somagenetix headquartered?

Somagenetix is headquartered in Zurich, Switzerland.

What does Somagenetix do?

Somagenetix is a new firm that wants to be a leader in gene therapy by developing first-in-class treatments for phagocyte-related illnesses.

What stage is Somagenetix at?

Somagenetix is at the Series A stage.

Cite this page

Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated October 8, 2024.

MLA

"Somagenetix — Funding & Investors." VCBacked, October 8, 2024, https://www.vcbacked.co/company/somagenetix. Accessed June 4, 2026.

APA

VCBacked. (2024). Somagenetix — Funding & Investors. Retrieved June 4, 2026, from https://www.vcbacked.co/company/somagenetix

Wikipedia (cite web)

{{cite web |title=Somagenetix — Funding & Investors |url=https://www.vcbacked.co/company/somagenetix |website=VCBacked |access-date=June 4, 2026}}

Profile data sourced and verified per the VCBacked methodology. Last funding round dated October 8, 2024.